TY - JOUR
T1 - INNV-21. FEASIBILITY OF A VIRTUAL REALITY (VR) INTERVENTION TARGETING DISTRESS AND ANXIETY IN PRIMARY BRAIN TUMOR (PBT) PATIENTS AT THE TIME OF NEUROIMAGING: INTERIM ANALYSIS OF A PHASE 2 CLINICAL TRIAL
AU - King, Amanda
AU - Roche, Kayla
AU - Leeper, Heather
AU - Vera, Elizabeth
AU - Mendoza, Tito
AU - Mentges, Kelly
AU - Acquaye, Alvina
AU - Adegbesan, Kendra
AU - Boris, Lisa
AU - Burton, Eric
AU - Chambers, Claudia
AU - Choi, Anna
AU - Christ, Alexa
AU - Evans, Karen
AU - Grajkowska, Ewa
AU - Levine, Jason
AU - Lindsley, Matthew
AU - Lollo, Nicole
AU - Komlodi-Pasztor, Edina
AU - Miller, Hope
AU - Panzer, Marissa
AU - Penas-Prado, Marta
AU - Pillai, Valentina
AU - Polskin, Lily
AU - Reyes, Jennifer
AU - Rogers, James
AU - Sahebjam, Solmaz
AU - Sass, Dilorom (Delia)
AU - Shuboni-Mulligan, Dorela
AU - Stockdill, Macy
AU - Theeler, Brett
AU - Wall, Kathleen
AU - Wollet, Alex
AU - Wu, Jing
AU - Gilbert, Mark
AU - Armstrong, Terri
PY - 2022/11
Y1 - 2022/11
N2 - Background/Purpose: PBT patients experience high levels of distress and anxiety symptoms at the time of neuroimaging (“scanxiety”). This single-arm phase 2 clinical trial interim analysis investigated the feasibility of an immersive VR intervention administered via telehealth for PBT populations. Methods: English-speaking adult patients with upcoming neuroimaging who can self-report symptoms and have reported distress on prior patient-reported outcomes (PROs) were eligible. Exclusion criteria include recent cranial surgery, scalp wounds, or seizures, anxiety disorders, nausea, and visual deficits. The primary intervention is a brief self-selected VR relaxation scenario completed prior to neuroimaging followed by self-directed use for 1 month. PROs are completed before and immediately after the intervention, as well as 1 week and 1 month later, with a qualitative phone interview to assess satisfaction. Results: Fifty-five screened patients were contacted via email with 15 (27%) no responses. 40 patients were approached with 9 (16%) declines, 11 (20%) screen fails, and 20 patients were consented and enrolled. Decline reasons included treatment-related symptoms (11%), no distress or anxiety (30%), and unknown (56%). Screen fail reasons included vertigo and incisional scalp pain (9%), recent seizure activity (9%), diplopia (9%), and anxiety disorders (9% claustrophobia/ panic disorder, 18% PTSD, and 36% GAD). Of those enrolled, 50% were male and the majority were 50 years old (65%), White/ non-Hispanic (90%), and had a KPS score of 90 (85%), a high-grade tumor (65%), and were on active treatment. 100% of enrolled patients completed the VR intervention, weekly check-ins, PRO questionnaires, and qualitative interview. >90% of patients found VR worthwhile, would use VR again, and would recommend VR to other patients for use before clinical evaluations. Conclusions and Implications: These findings suggest that VR intervention is feasible and study continuation is warranted. The high incidence of PTSD and GAD has not been previously reported and necessitates further exploration.
AB - Background/Purpose: PBT patients experience high levels of distress and anxiety symptoms at the time of neuroimaging (“scanxiety”). This single-arm phase 2 clinical trial interim analysis investigated the feasibility of an immersive VR intervention administered via telehealth for PBT populations. Methods: English-speaking adult patients with upcoming neuroimaging who can self-report symptoms and have reported distress on prior patient-reported outcomes (PROs) were eligible. Exclusion criteria include recent cranial surgery, scalp wounds, or seizures, anxiety disorders, nausea, and visual deficits. The primary intervention is a brief self-selected VR relaxation scenario completed prior to neuroimaging followed by self-directed use for 1 month. PROs are completed before and immediately after the intervention, as well as 1 week and 1 month later, with a qualitative phone interview to assess satisfaction. Results: Fifty-five screened patients were contacted via email with 15 (27%) no responses. 40 patients were approached with 9 (16%) declines, 11 (20%) screen fails, and 20 patients were consented and enrolled. Decline reasons included treatment-related symptoms (11%), no distress or anxiety (30%), and unknown (56%). Screen fail reasons included vertigo and incisional scalp pain (9%), recent seizure activity (9%), diplopia (9%), and anxiety disorders (9% claustrophobia/ panic disorder, 18% PTSD, and 36% GAD). Of those enrolled, 50% were male and the majority were 50 years old (65%), White/ non-Hispanic (90%), and had a KPS score of 90 (85%), a high-grade tumor (65%), and were on active treatment. 100% of enrolled patients completed the VR intervention, weekly check-ins, PRO questionnaires, and qualitative interview. >90% of patients found VR worthwhile, would use VR again, and would recommend VR to other patients for use before clinical evaluations. Conclusions and Implications: These findings suggest that VR intervention is feasible and study continuation is warranted. The high incidence of PTSD and GAD has not been previously reported and necessitates further exploration.
UR - https://www.mendeley.com/catalogue/2546a18c-57f8-3fd2-a7b4-1f538af71b0c/
U2 - 10.1093/neuonc/noac209.561
DO - 10.1093/neuonc/noac209.561
M3 - Article
SN - 1522-8517
VL - 24
SP - vii145-vii146
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - Supplement_7
ER -